Results 181 to 190 of about 53,817 (192)

Phase II study of everolimus–erlotinib in previously treated patients with advanced non-small-cell lung cancer

Annals of Oncology, 2014
V A Papadimitrakopoulou, J -C Soria, J Bennouna   +2 more
exaly  

Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study

Annals of Oncology, 2010
Emma Jane Dean, J Blatter, C Twelves
exaly  

Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy

Cancer Chemotherapy and Pharmacology, 2011
Shinichiro Ohshimo, Takeshi Masuda, Yoshinori Haruta   +2 more
exaly  

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study†

Annals of Oncology, 2015
Y-L Wu, Y Zuo
exaly  

Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects

Journal of Clinical Pharmacology, 2006
Steve Eppler, Marta Hamilton, Bert L Lum
exaly  

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC

Journal of Thoracic Oncology, 2018
Matthew D Hellmann, Jonathan W. Goldman, David E. Gerber   +2 more
exaly  

A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study†

Annals of Oncology, 2013
Anne-Marie Dingemans, O Dalésio, A D Vincent   +2 more
exaly  

Markers in the epidermal growth factor receptor pathway and skin toxicity during erlotinib treatment

Annals of Oncology, 2008
Seth M Steinberg, S M Steinberg, A R Tan
exaly  

The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects

Cancer Chemotherapy and Pharmacology, 2014
Marta Hamilton, Bert L Lum
exaly  

Role of Erlotinib in the Treatment of Non-Small Cell Lung Cancer

Drugs, 2012
Bilal Piperdi, Roman Perez-Soler
exaly